摄影机已架好。专访结束，我们想请德国科学院院士、汉诺威大学讲席教授尤尔根·卡罗录一段简短的 开场白，用在短视频里。 "正式的，还是非正式的？"他问。 "非正式一点，轻松就好。"我们答。 卡罗神情有些严肃，想了几秒，抬头看向镜头，刚说出两个单词，又忽然摆手："等一等。" 现场有些安静。我们以为这位教授有些疲倦了。 几秒后，他忽然转身，从包里翻出一本护照。"也许我可以从这里开始。"他翻开来，向镜头展示上面收 集的15个入境中国的印章，"我现在有了永久签证，可以更方便地来中国了，我喜欢中国。"他说。 一瞬间，现场笑开了花。这位严谨的科学家，原来是在设计小短片的桥段…… 这个小插曲，让人看到卡罗的另一面：他身上既有科学家的理性与克制，也有对世界的热情与幽默。 他的科学，从不冰冷。 1977年，他以优异成绩获得自然科学博士学位。在东德科学院解散后，科研机构骤然转向市场化。卡罗 从所长变成无依无靠的"自由科学家"。他带着十几名研究员，自筹经费，为企业定制催化剂维系实验 室。那是他人生中最艰难的两年，也是他重新理解科学意义的起点。 2023年10月，在清华大学举行的"巅峰对话"活动中，卡罗 （左）与2018年沃尔夫化学奖得 ...

Repligen (RGEN) FY Conference Summary Company Overview - Repligen positions itself as an innovation leader in bioprocessing, focusing heavily on R&D to launch unique products that enhance drug manufacturing efficiency, yield, and cost-effectiveness [4][5] - The company has a global manufacturing footprint with approximately 1,700 employees [5] - Sales distribution: 65% clinical and 35% commercial, with 80% of sales coming from monoclonal antibodies (mAbs) and 18% from new modalities [5][6] Market Insights - The mAbs market is projected to reach USD 250 billion in 2024, with a CAGR of 8% to 10% over the next five to ten years [7] - New modalities are expected to grow at a significantly higher CAGR of around 30% [9] - The total addressable market (TAM) for Repligen has increased from USD 4 billion to USD 12 billion over the past few years, indicating substantial growth potential [16][25] Financial Performance - Revenue increased tenfold, with EPS rising from $0.25 to $1.58 [15][16] - The company holds a 5% market share in its total addressable market, indicating significant room for growth [17] - In Q1, organic revenue growth was 14%, with order intake up nearly 20% compared to the previous year [42][43] Strategic Initiatives - Repligen has completed 15 acquisitions over the last several years, enhancing its product portfolio and market position [13][26] - The company aims to double its size in the next few years through organic growth and smaller acquisitions [17] - Focus on digitization and process automation to improve operational efficiency and customer experience [36][40] Product Portfolio - The product portfolio includes filtration, chromatography, and protein products, with a notable shift from protein to filtration as a key growth area [7][26] - New product innovations include ATF technology for process intensification and FlowVPX for inline concentration measurement, which enhance manufacturing efficiency [19][20] Customer Focus - Repligen emphasizes customer-centricity, aiming to improve customer experience and expand relationships across multiple product lines [47][50] - The company has diversified its customer base, reducing reliance on top customers from 81% to one-third of sales [33] Future Outlook - The company is focused on maintaining growth momentum, enhancing customer experience, and expanding margins by targeting a 100 to 200 basis point EBIT expansion in 2025 [48][49] - Continued investment in innovation and integration of recent acquisitions is a priority [50][51] Industry Trends - The bioprocessing market is expected to remain resilient, with significant opportunities in both commercial and clinical sectors [54] - There is a shift towards sourcing early-phase projects from outside the U.S., indicating a changing landscape in biopharma innovation [60][61]